We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 14, 2019

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Mucinous Histology

Clinical Colorectal Cancer

 

Additional Info

Clinical Colorectal Cancer
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component
Clin Colorectal Cancer 2019 Mar 06;[EPub Ahead of Print], R Moretto, F Morano, E Ongaro, et al

Further Reading